US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
GB9221220D0
(en)
*
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5258389A
(en)
*
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
US5310901A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
|
US5310903A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
Imidazolidyl rapamycin derivatives
|
GB9307491D0
(en)
*
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
US7279561B1
(en)
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
EP0710110B1
(en)
|
1993-04-23 |
2002-03-06 |
Abbott Laboratories |
Antibodies of ring opened rapamycins
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
JP4105761B2
(ja)
*
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
SK78196A3
(en)
*
|
1993-12-17 |
1997-02-05 |
Sandoz Ag |
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
US5362718A
(en)
*
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
IL115742A
(en)
|
1994-10-26 |
2000-06-01 |
Novartis Ag |
Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5621108A
(en)
*
|
1994-12-05 |
1997-04-15 |
Trustees Of The University Of Pennsylvania |
Processes and intermediates for preparing macrocycles
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6015815A
(en)
*
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US20030216303A1
(en)
*
|
1998-03-06 |
2003-11-20 |
Michael Ambuhl |
Emulsion preconcentrates containing cyclosporin or a macrolide
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US6790228B2
(en)
*
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US6670355B2
(en)
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
PT1318837E
(pt)
|
2000-08-11 |
2004-12-31 |
Wyeth Corp |
Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
|
DK1319008T3
(da)
|
2000-09-19 |
2009-02-09 |
Wyeth Corp |
Vandoplöselige rapamycinestere
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
RU2344821C2
(ru)
*
|
2002-07-30 |
2009-01-27 |
Уайт |
Парентеральные композиции, содержащие гидроксиэфиры рапамицина
|
PL375698A1
(en)
*
|
2002-09-06 |
2005-12-12 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
AU2003293529A1
(en)
*
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
ES2395082T3
(es)
*
|
2003-01-27 |
2013-02-08 |
Endocyte, Inc. |
Conjugado de folato-vinblastina como medicamento
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
ME00294B
(me)
*
|
2003-07-23 |
2011-05-10 |
Bayer Pharmaceuticals Corp |
Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
|
CN1882338A
(zh)
*
|
2003-09-18 |
2006-12-20 |
马库赛特公司 |
经巩膜递送
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
US8431145B2
(en)
*
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
ATE534424T1
(de)
*
|
2004-03-19 |
2011-12-15 |
Abbott Lab |
Mehrfache arzneiabgabe aus einem ballon und eine prothese
|
DE602005010228D1
(de)
|
2004-04-14 |
2008-11-20 |
Wyeth Corp |
Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
|
CA2562164A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
CA2571899A1
(en)
*
|
2004-07-01 |
2006-08-03 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
WO2006012527A1
(en)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Bivalent linkers and conjugates thereof
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
CA2582374A1
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
CN101048152A
(zh)
*
|
2004-10-28 |
2007-10-03 |
惠氏公司 |
mTOR抑制剂在治疗子宫平滑肌瘤中的应用
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
US20060258698A1
(en)
*
|
2005-02-09 |
2006-11-16 |
Sreenivasu Mudumba |
Liquid formulations for treatment of diseases or conditions
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
EP1863816B1
(en)
*
|
2005-03-16 |
2014-06-25 |
Endocyte, Inc. |
Synthesis and purification of pteroic acid and conjugates thereof
|
KR20070121754A
(ko)
*
|
2005-03-21 |
2007-12-27 |
마커사이트, 인코포레이티드 |
질환 또는 상태의 치료를 위한 약물 송달 시스템
|
JP5271697B2
(ja)
*
|
2005-03-23 |
2013-08-21 |
アボット ラボラトリーズ |
医療装置を介する高親油性薬剤の送達
|
JP5242374B2
(ja)
|
2005-03-23 |
2013-07-24 |
アボット・ラボラトリーズ |
組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
|
EP1886138A4
(en)
*
|
2005-05-11 |
2009-04-15 |
Genetic Technologies Ltd |
PROCESS FOR ENRICHING FETTAL CELLS
|
MX2008000897A
(es)
|
2005-07-20 |
2008-03-18 |
Novartis Ag |
Combinacion de una pirimidil-amino-benzamida y un inhibidor de cinasa mtor.
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
ES2468240T3
(es)
*
|
2005-08-19 |
2014-06-16 |
Endocyte, Inc. |
Conjugados de ligando de múltiples fármacos
|
EP1942937A1
(en)
|
2005-11-04 |
2008-07-16 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
EP1956906A4
(en)
|
2005-11-09 |
2009-12-30 |
Combinatorx Inc |
METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
PE20071067A1
(es)
*
|
2005-12-20 |
2007-11-26 |
Wyeth Corp |
Composiciones de rapamicina y cci-779 y metodo para su preparacion
|
US20070196850A1
(en)
*
|
2006-01-27 |
2007-08-23 |
University Of Washington |
Identification of aging genes through large-scale analysis
|
US8492400B2
(en)
*
|
2006-02-09 |
2013-07-23 |
Santen Pharmaceutical Co., Ltd. |
Stable formulations, and methods of their preparation and use
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
US7678901B2
(en)
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
JP5506378B2
(ja)
|
2006-03-23 |
2014-05-28 |
参天製薬株式会社 |
血管透過性に関連する疾患または病気のための製剤および方法
|
US7883855B2
(en)
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
EP2702993B1
(en)
|
2006-09-13 |
2017-12-06 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
US20080097591A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080103584A1
(en)
*
|
2006-10-25 |
2008-05-01 |
Biosensors International Group |
Temporal Intraluminal Stent, Methods of Making and Using
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US20080175887A1
(en)
|
2006-11-20 |
2008-07-24 |
Lixiao Wang |
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
WO2008101231A2
(en)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
US20100151436A1
(en)
*
|
2007-03-02 |
2010-06-17 |
Fong Peter M |
Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
|
EP2489372A3
(en)
|
2007-03-14 |
2013-01-02 |
Endocyte, Inc. |
Binding ligand linked drug delivery conjugates of tubulysins
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
JP2008305262A
(ja)
*
|
2007-06-08 |
2008-12-18 |
Konica Minolta Business Technologies Inc |
サーバ及びシンクライアント環境でのプリンタ紹介方法
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
CA2690943A1
(en)
|
2007-06-25 |
2008-12-31 |
Endocyte, Inc. |
Conjugates containing hydrophilic spacer linkers
|
BRPI0814060A2
(pt)
*
|
2007-07-06 |
2015-01-06 |
Trubion Pharmaceuticals Inc |
Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
ES2559311T3
(es)
|
2007-12-19 |
2016-02-11 |
Abbott Laboratories |
Reactivo de extracción de fármacos inmunosupresores para inmunoanálisis
|
WO2009117669A2
(en)
|
2008-03-21 |
2009-09-24 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
DK2132228T3
(da)
|
2008-04-11 |
2011-10-10 |
Emergent Product Dev Seattle |
CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
KR20110074758A
(ko)
*
|
2008-10-03 |
2011-07-01 |
엘릭서 메디컬 코포레이션 |
마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
|
CN104042612A
(zh)
|
2008-11-11 |
2014-09-17 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
CN102686600A
(zh)
|
2009-02-05 |
2012-09-19 |
托凯药业股份有限公司 |
甾体cyp17抑制剂/抗雄激素物质的新型药物前体
|
EP2762142A1
(en)
|
2009-10-30 |
2014-08-06 |
ARIAD Pharmaceuticals, Inc. |
Compositions for treating cancer
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
CN102869358B
(zh)
|
2010-04-13 |
2016-03-23 |
诺华股份有限公司 |
用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
|
BR112012026285A2
(pt)
|
2010-04-16 |
2016-07-12 |
Novartis Ag |
combinação de compostos orgânicos
|
EP2563391B1
(en)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
KR101253399B1
(ko)
|
2010-10-26 |
2013-04-11 |
영남대학교 산학협력단 |
아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
|
CA2852056C
(en)
|
2011-03-11 |
2021-08-10 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
CN103491955B
(zh)
|
2011-04-25 |
2015-12-23 |
诺华股份有限公司 |
磷脂酰肌醇-3-激酶(pi3k)抑制剂及mtor抑制剂的组合
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
ES2574522T3
(es)
|
2012-06-08 |
2016-06-20 |
Biotronik Ag |
Ésteres 40-O-hidrocarburo cíclico de rapamicina, composiciones y procedimientos
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US20150290176A1
(en)
|
2012-10-12 |
2015-10-15 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
WO2014062697A2
(en)
|
2012-10-16 |
2014-04-24 |
Endocyte, Inc. |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
WO2014078522A1
(en)
|
2012-11-14 |
2014-05-22 |
Ohio State Innovation Foundation |
Materials and methods useful for treating glioblastoma
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
CA2904170A1
(en)
|
2013-03-14 |
2014-09-25 |
University Of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
AU2014248090B2
(en)
|
2013-04-03 |
2018-08-02 |
N-Fold Llc |
Novel nanoparticle compositions
|
CN105636594A
(zh)
|
2013-08-12 |
2016-06-01 |
托凯药业股份有限公司 |
使用雄激素靶向疗法用于***性疾病的生物标记物
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
BR112016014903A8
(pt)
|
2014-02-11 |
2018-05-02 |
Novartis Ag |
combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
EP3131546B1
(en)
|
2014-04-16 |
2022-02-16 |
Rapamycin Holdings, Inc. |
Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
WO2015187541A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
CN107073066B
(zh)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
EP3204121B1
(en)
|
2014-10-08 |
2019-06-19 |
Epigenetics Pharma LLC |
Silylated 5-aza-pyrimidine prodrugs useful for treating cancer
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
AU2017290143A1
(en)
|
2016-06-30 |
2019-02-21 |
Durect Corporation |
Depot formulations
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
EA201990127A1
(ru)
|
2016-12-30 |
2020-08-18 |
Дьюрект Корпорейшн |
Депо-препарат
|
SG11201908226XA
(en)
|
2017-02-10 |
2019-10-30 |
Mount Tam Therapeutics Inc |
Rapamycin analog
|
US20210154372A1
(en)
|
2017-05-15 |
2021-05-27 |
C.R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
WO2019012024A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
UY37900A
(es)
|
2017-09-26 |
2019-04-30 |
Novartis Ag |
Nuevos derivados de rapamicina
|
ES2945560T3
(es)
|
2018-05-01 |
2023-07-04 |
Revolution Medicines Inc |
Análogos de rapamicina unidos en C40, C28 y C-32 como inhibidores de mTOR
|
IL278335B1
(en)
|
2018-05-01 |
2024-05-01 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as MTOR inhibitors
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
CA3107349A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
WO2020023418A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
JP7262581B2
(ja)
|
2018-11-14 |
2023-04-21 |
ルトニックス,インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
EP3952947A4
(en)
|
2019-04-11 |
2024-07-03 |
Enclear Therapies Inc |
METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
AU2020372881A1
(en)
|
2019-10-28 |
2022-06-09 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2022014640A1
(ja)
|
2020-07-15 |
2022-01-20 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN117769554A
(zh)
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|